Study of SGR-1505 in Mature B-Cell Neoplasms

Recruiting now · Phase 1

Conditions studied: Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma

In brief

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

Key facts

Study ID

NCT05544019

Run by

Schrödinger, Inc.

People needed

98

Starts

2023-04-10

Expected to finish

2027-11-01

Last updated by the study team

2026-02-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject must have a history of histologically or cytologically confirmed mature B-cell malignancy.
• Subject must have measurable or detectable disease according to the applicable disease-specific classification system and meet criteria for initiation of treatment.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Life expectancy ≥ 12 weeks.

You may not qualify if…

• The subject is in need of immediate cytoreductive therapy (unless the patient has no remaining treatment choice with potential benefit).
• Subject has previous invasive malignancy in the last 2 years.
• Subject has a known allergy to SGR-1505 or excipients of SGR-1505.
• Subject has symptomatic or active CNS involvement of disease.
• Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that would place the participant at increased risk to the use of an investigational drug.

Where it is running

• Banner Health - MD Anderson Cancer Center — Gilbert, Arizona, United States (enrolling)
• Christiana Care Hospital - Helen F Graham Cancer Center — Newark, Delaware, United States (enrolling)
• Napa Research — Pompano Beach, Florida, United States (enrolling)
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States (enrolling)
• Regional Cancer Care Associates — Hackensack, New Jersey, United States (enrolling)
• Roswell Park Comprehensive Cancer Center — Buffalo, New York, United States (enrolling)
• Weill Cornell — New York, New York, United States (enrolling)
• Montefiore Medical Center — The Bronx, New York, United States (enrolling)
• Duke University — Durham, North Carolina, United States (enrolling)
• Gabrail Cancer & Research Center — Canton, Ohio, United States (enrolling)
• The Ohio State University - The James Cancer Hospital — Columbus, Ohio, United States (enrolling)
• Oregon Health and Science University - Knight Cancer Institute — Portland, Oregon, United States (enrolling)
• Rhode Island Hospital — Providence, Rhode Island, United States (enrolling)
• University of Texas Southwestern — Dallas, Texas, United States (enrolling)
• Fred Hutchinson Cancer Center — Seattle, Washington, United States (enrolling)
• Medical College of Wisconsin — Milwaukee, Wisconsin, United States (enrolling)
• AP-HP Hôpital Henri-Mondor — Créteil, France (enrolling)
• Institut Gustave Roussy — Villejuif, France (enrolling)
• Azienda Ospedaliera Nazionale SS. Antonio e Biagio e C. Arrigo - Presidio Ospedaliero SS Antonio e Biagio e Cesare Arrigo, Ospedale Civile — Alessandria, Italy (enrolling)
• ASST Grande Ospedale Metropolitano Niguarda — Milan, Italy (enrolling)
• IRCCS Ospedale San Raffaele — Milan, Italy (enrolling)
• AOU Citta della Salute e della Scienza di Torino - Ospedale le Molinette — Torino, Italy (enrolling)
• Azienda Ospedaliera - Universitaria Integrata di Verona - Ospedale Borgo Roma — Verona, Italy (enrolling)
• Institute of Oncology, ARENSIA Exploratory Medicine — Chisinau, Moldova (enrolling)
• Uniwersyteckie Centrum Kliniczne, Osrodek Badan Klinicznych Wczesnych Faz — Gdansk, Poland (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.